Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

  title={Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.},
  author={Hayley J Sharpe and Gregoire Pau and Gerrit J. P. Dijkgraaf and Nicole Basset-S{\'e}guin and Zora Modrusan and Thomas Januario and Vickie Tsui and Alison B Durham and Andrzej A Dlugosz and Peter M. Haverty and Richard Bourgon and Jean Yuh Tang and Kavita Y Sarin and Luc Y Dirix and David C. Fisher and Charles M Rudin and H Sofen and Michael R. Migden and Robert L. Yauch and Frederic J de Sauvage},
  journal={Cancer cell},
  volume={27 3},
Smoothened (SMO) inhibitors are under clinical investigation for the treatment of several cancers. Vismodegib is approved for the treatment of locally advanced and metastatic basal cell carcinoma (BCC). Most BCC patients experience significant clinical benefit on vismodegib, but some develop resistance. Genomic analysis of tumor biopsies revealed that vismodegib resistance is associated with Hedgehog (Hh) pathway reactivation, predominantly through mutation of the drug target SMO and to a… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 45 extracted citations

Hedgehog Signaling: From Basic Biology to Cancer Therapy.

Cell chemical biology • 2017
View 7 Excerpts
Highly Influenced

Hedgehog Signaling Pathway and Autophagy in Cancer

International journal of molecular sciences • 2018
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 52 references

Similar Papers

Loading similar papers…